Valuation : Tibet Duo Rui Pharmaceutical Co., Ltd.

Market Cap 482.73Cr 72Cr 62Cr 58Cr 53Cr 99Cr 6.79TCr 100Cr 687.9Cr 266.94Cr 3.48TCr 270.01Cr 264.12Cr 11TCr P/E 2024
-22.7x
P/E 2025 -46.3x
Enterprise Value 515.41Cr 77Cr 66Cr 62Cr 57Cr 106.21Cr 7.25TCr 106.5Cr 734.46Cr 285Cr 3.72TCr 288.28Cr 281.99Cr 12TCr EV / Sales 2024
6.46x
EV / Sales 2025 32.7x
Free-Float
30.57%
Yield 2024 *
-
Yield 2025 -
26/08 Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
28/04 Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
23/04 Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
23/04 Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Hubei Hairuidi Pharmaceutical Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 2.4 million. CI
23/04 Tibet Jiakang TImes Technology Development Co., Ltd. entered into an Equity Transfer Agreement to acquire 69% stake in Xiamen Ruitilian Pharmaceutical Technology Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 27.6 million. CI
23/04 Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Wuhan Duorui Industrial Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 5.1 million. CI
27/02 Wang Qingtai and Cao Xiaobing completed the acquisition of an additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd. CI
24/02 Trading in Tibet Duo Rui Pharmaceutical's shares to halt RE
21/01 Wang Qingtai and Cao Xiaobing proposed to acquire additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 620 million. CI
05/12 Wang Qingtai, Cui Zihao and Cao Xiaobing completed the acquisition of 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd. CI
23/25/23 Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
13/25/13 Wang Qingtai, Cui Zihao and Cao Xiaobing signed an share transfer agreement to acquire 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 760 million. CI
29/25/29 Duorui Pharma Expects Control Change Amid Parents' Plan MT
1 day-1.02%
1 week+10.32%
Current month+5.78%
1 month+9.77%
3 months-15.87%
6 months-27.08%
Current year+2.46%
1 week 55.9
Extreme 55.9
63.66
1 month 51.5
Extreme 51.5
63.66
Current year 44.55
Extreme 44.55
98.29
1 year 39.1
Extreme 39.1
98.29
3 years 12.6
Extreme 12.6
98.29
5 years 12.6
Extreme 12.6
98.29
10 years 12.6
Extreme 12.6
98.29
Manager TitleAgeSince
Chief Executive Officer 60 01/12/2018
Director of Finance/CFO 47 01/05/2017
Director of Finance/CFO 46 01/12/2017
Director TitleAgeSince
Chairman 60 01/12/2017
Director/Board Member 70 21/02/2020
Director/Board Member 58 21/02/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.02%+10.32%+31.31%+127.46% 72Cr
-0.88%-2.15%+58.05%+105.26% 1,02400Cr
-1.15%+2.68%+54.25%+74.19% 66TCr
-1.44%+0.38%+20.65%+76.13% 45TCr
-0.56%+0.65%+31.47%+38.36% 35TCr
-2.52%+2.58%+23.57%+42.66% 30TCr
+1.57%+1.96%+1.89%+12.68% 25TCr
-1.55%+1.11%+54.15%+75.59% 24TCr
-0.20%+2.17%-13.89%-55.83% 21TCr
-0.15%+3.65%+31.24%+103.39% 19TCr
Average -0.79%+1.72%+29.27%+59.99% 36.79TCr
Weighted average by Cap. -0.90%+0.62%+37.88%+67.16%

Financials

2024 2025
Net sales 24Cr 3.58Cr 3.08Cr 2.9Cr 2.65Cr 4.96Cr 338.4Cr 4.97Cr 34Cr 13Cr 173.62Cr 13Cr 13Cr 559.34Cr 15Cr 2.3Cr 1.98Cr 1.86Cr 1.7Cr 3.18Cr 216.82Cr 3.19Cr 22Cr 8.53Cr 111.25Cr 8.62Cr 8.44Cr 358.38Cr
Net income -6.27Cr -93.34L -80.32L -75.57L -69.03L -1.29Cr -88Cr -1.29Cr -8.93Cr -3.47Cr -45Cr -3.51Cr -3.43Cr -145.67Cr -10Cr -1.52Cr -1.31Cr -1.23Cr -1.13Cr -2.11Cr -143.69Cr -2.11Cr -15Cr -5.65Cr -74Cr -5.71Cr -5.59Cr -237.49Cr
Net Debt 13Cr 2.01Cr 1.73Cr 1.62Cr 1.48Cr 2.78Cr 189.41Cr 2.78Cr 19Cr 7.45Cr 97Cr 7.53Cr 7.37Cr 313.08Cr 33Cr 4.87Cr 4.19Cr 3.94Cr 3.6Cr 6.73Cr 459.5Cr 6.75Cr 47Cr 18Cr 235.76Cr 18Cr 18Cr 759.5Cr
Logo Tibet Duo Rui Pharmaceutical Co., Ltd.
Tibet Duo Rui Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical preparations, intermediates and active pharmaceutical ingredients. The Company mainly has self-produced products such as Sodium Acetate Ringer Injection and agent products such as Amoxicillin Sodium and Clavulanate Potassium for Injection. The Company's products mainly include liquid therapy, emergency medication, pediatric medication, psychiatric medication, and analgesic medication. The Company mainly operates its businesses in the domestic market.
Employees
461
Date Price Change Volume
04/26/04 CN¥61.14 -1.02% 10,70,800
03/26/03 CN¥61.77 +2.30% 14,73,400
02/26/02 CN¥60.38 +4.07% 16,93,101
01/26/01 CN¥58.02 +0.38% 12,08,390
31/26/31 CN¥57.80 +4.29% 16,79,900
  1. Stock Market
  2. Stocks
  3. 301075 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!